Permeability of lipophilic compounds in drug discovery using in-vitro human absorption model, Caco-2.

[1]  W. R. Bishop,et al.  Identification of pharmacokinetically stable 3, 10-dibromo-8-chlorobenzocycloheptapyridine farnesyl protein transferase inhibitors with potent enzyme and cellular activities. , 1999, Journal of medicinal chemistry.

[2]  K. Luthman,et al.  Caco-2 monolayers in experimental and theoretical predictions of drug transport , 1996 .

[3]  A. Waseem Malick,et al.  The use of the intestinal epithelial cell culture model, Caco-2, in pharmaceutical development , 1996 .

[4]  O. H. Chan,et al.  Absorption of Cam-2445, and NK1 neurokinin receptor antagonist: in vivo, in situ, and in vitro evaluations. , 1996, Journal of pharmaceutical sciences.

[5]  D. Scherman,et al.  High lipophilicity decreases drug transport across intestinal epithelial cells. , 1994, The Journal of pharmacology and experimental therapeutics.

[6]  P. Augustijns,et al.  Evidence for a polarized efflux system in CACO-2 cells capable of modulating cyclosporin A transport. , 1993, Biochemical and biophysical research communications.

[7]  T. Tsuruo,et al.  Functional expression of P-glycoprotein in apical membranes of human intestinal Caco-2 cells. Kinetics of vinblastine secretion and interaction with modulators. , 1993, The Journal of biological chemistry.

[8]  C. Higgins,et al.  Specific inhibitors distinguish the chloride channel and drug transporter functions associated with the human multidrug resistance P-glycoprotein. , 1993, Receptors & channels.

[9]  P. Nicklin,et al.  Permeable support type influences the transport of compounds across Caco-2 cells , 1992 .

[10]  B Irollo,et al.  Dissociation and association rate constants changes following bilirubin binding affinity decreases. , 1987, Developmental pharmacology and therapeutics.